catalyst · primary record
Empasiprubart IV + Placebo IV
Phase readout · 2027-10-07 · Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
| Company | argenx |
|---|---|
| Ticker | Not stated |
| Impact | high |
| Detail | P3 primary completion · NCT07091630 |
| Source | ClinicalTrials.gov |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T10:39:29.149Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: argenx:Empasiprubart IV + Placebo IV:2027-10-07:P3 primary completion · NCT07091630
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.